Colo-rectal Cancer Clinical Trial
Official title:
The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer
Verified date | October 2022 |
Source | Tanta University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to: - Evaluate the possible protective effect of pentoxifylline against oxaliplatin induced peripheral neuropathy and chemotherapy induced mucositis in patients with stage II and stage III colorectal cancer. This study will be a randomized placebo controlled parallel study.48 patients with colorectal cancer will be randomized to 2 groups: Group I (control group; n=24) which will receive 12 cycles of FOLFOX-6 regimen plus placebo tablets twice daily. Group II (Pentoxiphylline group; n=24) which will receive FOLFOX-6 regimen in addition to pentoxifylline 400 mg twice daily. Blood sample collection and biochemical assessment: - Malondialdehyde (MDA) as oxidative stress marker (colorimetry). - Tumor necrosis factor alfa (TNF-α) as pro inflammatory marker (ELISA). - Neurotensin (NT) as a potential marker for neuropathic pain (ELISA). - Citrulline as a biomarker for mucositis (ELISA). Clinical assessment of oxaliplatin induced neuropathy will be done through: The assessment of the severity of neuropathic pain through "Brief Pain Inventory-Short Form" at baseline and by the end of every two chemotherapy cycles. The implication of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 5, 2017) for grading of neuropathy every 2 cycles. The use of Neurotoxicity- 12 item questionnaire score (Ntx-12) from the validated Functional Assessment of Cancer Therapy/Gynecologic Oncology Group at baseline and by the end of every two chemotherapy cycles). Mucositis will be assessed at baseline and by the end of every two chemotherapy cycles through the use of common terminology criteria for adverse events "CTCAE, version 5.00, 2017
Status | Enrolling by invitation |
Enrollment | 48 |
Est. completion date | October 11, 2024 |
Est. primary completion date | October 11, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - - Patients with histologically confirmed diagnosis of stage II and stage III colorectal cancer. - Patients who will be scheduled to receive FOLFOX-6 regimen. - Patients with no contraindication to chemotherapy. - Males and females aged = 18 years old. - Adequate baseline hematologic values (absolute neutrophilic count = 1.5 × 109/L, platelet count = 100 × 109/L and hemoglobin level = 10 g/dl). - Patients with adequate renal function (serum creatinine < 1.5 mg/dL and Creatinine clearance (ClCr) ? 45 mL/min). - Patients with adequate liver function (serum bilirubin < 1.5 mg/dl). - Patients with performance status < 2 according to Eastern Cooperative Oncology Group (ECOG) score. Exclusion Criteria: - - Children < 18 years old. - Prior exposure to neurotoxic chemotherapy (oxaliplatin, cisplatin, vincristine, paclitaxel, docetaxel or Isoniazid) for at least 6 months prior the study treatment. - Evidence of pre-existing peripheral neuropathy resulting from another reason (diabetes, brain tumor or brain trauma). - Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases or hepatitis C. - History of known allergy to oxaliplatin or other platinum agents. - Patients with other inflammatory diseases (rheumatoid arthritis and ulcerative colitis) or stressful conditions (obesity class 2 and 3, smoking). - Concomitant use of multivitamins (vitamins E, C and A), tricyclic antidepressants or other neuro-protective medications (gabapentin, lamotrigine, carbamazepine and phenytoin, etc...). - Concurrent active cancer originating from a primary site other than colon or rectum. - Patients on blood thinning agents - Pregnant and breastfeeding women |
Country | Name | City | State |
---|---|---|---|
Egypt | Tanta University | Tanta | Gharbyia |
Lead Sponsor | Collaborator |
---|---|
Tanta University |
Egypt,
Al Moundhri MS, Al-Salam S, Al Mahrouqee A, Beegam S, Ali BH. The effect of curcumin on oxaliplatin and cisplatin neurotoxicity in rats: some behavioral, biochemical, and histopathological studies. J Med Toxicol. 2013 Mar;9(1):25-33. doi: 10.1007/s13181-012-0239-x. — View Citation
André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ; for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013;9:261-269. Review. — View Citation
Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel). 2019 Jun 20;11(6). pii: E857. doi: 10.3390/cancers11060857. Review. — View Citation
Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract. 2011 Jul;93(1):56-62. doi: 10.1016/j.diabres.2010.11.030. Epub 2010 Dec 13. — View Citation
Fragkos KC, Forbes A. Citrulline as a marker of intestinal function and absorption in clinical settings: A systematic review and meta-analysis. United European Gastroenterol J. 2018 Mar;6(2):181-191. doi: 10.1177/2050640617737632. Epub 2017 Oct 12. Review. — View Citation
Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021 Jan;112(1):90-92. doi: 10.1016/j.ad.2019.05.009. Epub 2020 Sep 3. English, Spanish. — View Citation
Guren MG. The global challenge of colorectal cancer. Lancet Gastroenterol Hepatol. 2019 Dec;4(12):894-895. doi: 10.1016/S2468-1253(19)30329-2. Epub 2019 Oct 21. — View Citation
Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, Gansl RC. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer. 2012 Jun;11(2):93-100. doi: 10.1016/j.clcc.2011.10.004. Epub 2011 Dec 6. Review. — View Citation
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732. doi: 10.1038/s41575-019-0189-8. Epub 2019 Aug 27. Review. — View Citation
Kidwell KM, Yothers G, Ganz PA, Land SR, Ko CY, Cecchini RS, Kopec JA, Wolmark N. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer. 2012 Nov 15;118(22):5614-22. doi: 10.1002/cncr.27593. Epub 2012 May 8. — View Citation
Kleczkowska P, Lipkowski AW. Neurotensin and neurotensin receptors: characteristic, structure-activity relationship and pain modulation--a review. Eur J Pharmacol. 2013 Sep 15;716(1-3):54-60. doi: 10.1016/j.ejphar.2013.03.004. Epub 2013 Mar 14. Review. — View Citation
Plaza-Manzano G, Molina-Ortega F, Lomas-Vega R, Martínez-Amat A, Achalandabaso A, Hita-Contreras F. Changes in biochemical markers of pain perception and stress response after spinal manipulation. J Orthop Sports Phys Ther. 2014 Apr;44(4):231-9. doi: 10.2519/jospt.2014.4996. Epub 2014 Jan 22. — View Citation
Saito Y, Okamoto K, Kobayashi M, Narumi K, Furugen A, Yamada T, Iseki K. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration. Life Sci. 2017 Nov 15;189:18-22. doi: 10.1016/j.lfs.2017.08.028. Epub 2017 Aug 31. — View Citation
Salehifar E, Janbabaei G, Hendouei N, Alipour A, Tabrizi N, Avan R. Comparison of the Efficacy and Safety of Pregabalin and Duloxetine in Taxane-Induced Sensory Neuropathy: A Randomized Controlled Trial. Clin Drug Investig. 2020 Mar;40(3):249-257. doi: 10.1007/s40261-019-00882-6. — View Citation
Speer EM, Dowling DJ, Ozog LS, Xu J, Yang J, Kennady G, Levy O. Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns. Pediatr Res. 2017 May;81(5):806-816. doi: 10.1038/pr.2017.6. Epub 2017 Jan 10. — View Citation
Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain. 2004 Mar;5(2):133-7. — View Citation
Vondracek P, Oslejskova H, Kepak T, Mazanek P, Sterba J, Rysava M, Gal P. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. 2009 Jul;13(4):332-6. doi: 10.1016/j.ejpn.2008.06.011. Epub 2008 Sep 6. — View Citation
Yehia R, Saleh S, El Abhar H, Saad AS, Schaalan M. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-?B pathways. Toxicol Appl Pharmacol. 2019 Feb 15;365:41-50. doi: 10.1016/j.taap.2018.12.015. Epub 2018 Dec 25. — View Citation
Zanardelli M, Micheli L, Cinci L, Failli P, Ghelardini C, Di Cesare Mannelli L. Oxaliplatin neurotoxicity involves peroxisome alterations. PPAR? agonism as preventive pharmacological approach. PLoS One. 2014 Jul 18;9(7):e102758. doi: 10.1371/journal.pone.0102758. eCollection 2014. — View Citation
Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2014 Jun;13(2):73-80. doi: 10.1016/j.clcc.2013.11.004. Epub 2013 Nov 13. Review. — View Citation
* Note: There are 20 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | percentage of patients with peripheral sensory neuropathy grade = 2 | Grading according to National Cancer Institute Common Terminology. there are 5 grades; Grade (1) is asymptomatic may be accompanied by loss of tendon reflex or paresthesia. Grade (2) is moderate symptoms which limit instrumental activities of daily life Grade (3) is severe symptoms which limit self-care activates of daily life. Grade (4) is life threatening consequences or urgent intervention indicated. Grade (5) is death.
Criteria for Adverse Events (NCI-CTCAE, Version 5, 2017) |
6 months | |
Primary | variation of 12-item neurotoxicity questionnaire (Ntx- 12) total score | the Ntx-12 questionnaire is comprised of 12 statements intended to measure the severity and impact of peripheral sensory neuropathy on patients' lives. Patients will be instructed to complete the Arabic version of the Ntx-12 and choose the number corresponding to how true each statement was for them using a likert-type scale, with 0 indicating not at all; 1, a little bit; 2, somewhat; 3, quite a bit; and 4, very much | 6 months | |
Primary | variation in grades of mucositis | Mucositis will be assessed through the use of common terminology criteria for adverse events "CTCAE, version 5.00, 2017". Grade (1) is Asymptomatic or mild symptoms; intervention not indicated. Grade (2) is Moderate pain or ulcer that does not interfere with oral intake; modified diet indicated. Grade (3) is Severe pain, interfering with oral intake. Grade (4) is Life-threatening consequences; urgent intervention indicated. Grade (5) is Death. | 6 months | |
Secondary | Change in the biological marker Malondialdehyde | Malondialdehyde (MDA) as oxidative stress marker will be measured using colorimetry | 6 months | |
Secondary | Change in the biological marker Tumor necrosis factor alfa | Tumor necrosis factor alfa (TNF-a) as pro inflammatory marker will be measured using ELISA will be measured using (ELISA). | 6 months | |
Secondary | Change in the biological marker Neurotensin | Neurotensin (NT) as a potential marker for neuropathic pain will be measured using ELISA | 6 months | |
Secondary | Change in the biological marker Citrulline | Citrulline as a biomarker for mucositis will be measured using ELISA | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05074966 -
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts
|
Phase 3 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT05056389 -
Normothermic Intraperitoneal Chemotherapy - Long Term in Peritoneal Metastases From Colorectal Cancer (NIPEC-OXA)
|
Phase 1 | |
Completed |
NCT04551001 -
Evaluation of Cold Forcep and Cold Snare Polypectomy for Polyps Less Than or Equal to 3mm in Size During Colonoscopy
|
N/A | |
Completed |
NCT04551014 -
Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm
|
N/A | |
Recruiting |
NCT04270500 -
The Impact of Physical Exercise on Sleep in Colorectal Cancer Patients During Prehabilitation Period
|
N/A | |
Recruiting |
NCT03667911 -
Virtual Reality Videos in Improving Bowel Preparation Quality of Colonoscopy
|
N/A | |
Not yet recruiting |
NCT04073680 -
A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05572684 -
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Suspended |
NCT04108481 -
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03567850 -
Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC
|
N/A | |
Recruiting |
NCT05870332 -
Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy
|
||
Completed |
NCT04534218 -
Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT03129139 -
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04195646 -
Computer Aided Detection of Polyps During Colonoscopy Procedures
|
N/A | |
Not yet recruiting |
NCT03261752 -
New Genes in the Carcinogenesis of Colorectal Cancer
|
||
Not yet recruiting |
NCT03618329 -
Effect of Prehabilitation on the Lean Mass Index (IMM) in ERAS PROGRAMM.
|
N/A | |
Terminated |
NCT03621982 -
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03741166 -
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.
|